Search results
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
Hugh Auchincloss's 83 research works with 7,196 citations and 3,574 reads, including: CTLA-4: Not all Costimulation is Stimulatory ... immunologists and molecular biologists gathered in Vienna in ...
Oct 17, 2023 · Dr. Hugh Auchincloss, NIAID Principal Deputy Director, welcomes the NIAID DP2 New Innovator awardees and is proud to support these exceptional early-career investigators in their movement into independent positions.
Sep 15, 2023 · The new clinical trial is expected to enroll 24 healthy volunteers, aged 18-50 years, who will receive two intramuscular injections of the FluMos-v2 vaccine candidate. These injections will be given 16 weeks apart. At first, participants will be enrolled in the lower dose group (60 mcg per vaccination). If no safety concerns are identified ...
Jun 17, 2015 · G. Wayne Miller . Journal Staff Writer. NEWPORT, R.I. — Hugh D. “Yusha” Auchincloss III, a member of one of Newport’s most historically prominent families, died early Saturday morning at ...
Jan 20, 2023 · Auchincloss Named Acting Director for NIAID. Dr. Hugh Auchincloss. Dr. Hugh Auchincloss has agreed to serve as acting director of the National Institute of Allergy and Infectious Diseases (NIAID). Auchincloss assumed the acting role on Jan. 1. He has served as NIAID’s principal deputy director since joining NIH in 2006.
Apr 2, 2022 · Hugh Auchincloss Jr. is an American immunologist and physician serving as the principal deputy director of the National Institute of Allergy and Infectious diseases since 2006. He was previously a transplant surgeon and professor of surgery at Harvard Medical School and researched at Massachusetts General Hospital for 17 years.
